丙戊酸钠治疗精神分裂症患者攻击行为的临床疗效及安全性分析

Clinical Efficacy and Safety Analysis of Valproate in the Treatment of Aggressive Behavior in Patients with Schizophrenia

目的 分析精神分裂症患者行丙戊酸钠辅助治疗的临床效果。方法 选取我院在2014年1月3日至2016年1月1日收取的精神分裂症患者120例,根据治疗时间段分为研究组(n=60)和对照组(n=60)。对照组行奥氮平治疗,研究组在对照组的基础上加用丙戊酸钠治疗。记录两组治疗前后的PANSS、MOAS以及不良反应发生情况,对比两组患者的精神病评定量表(BPRS)、不良反应量表(TESS)评分、精神分裂症认知功能成套测验(MCCB)评分。结果 两组治疗后的第1周末、第2周末、第4周末PANSS分值相对于治疗前显著降低(P<0.05)。在治疗的第2周末和第4周末,研究组PANSS分值低于对照组,两组对比具有统计学差异(P<0.05);研究组和对照组治疗后各个阶段MOAS分数较比治疗前有所降低,组间比较存在差异性(P<0.05),研究组治疗第2周末和第4周末,MOAS分值低于对照组,组间存在统计学意义(P<0.05);两组不良反应发生率对比,基本无统计学意义(P>0.05)。治疗后,研究组患者的BPRS、TESS评分均低于对照组,MCCB评分高于对照组,比较存在差异性(P<0.05),经过对症处理后得到好转。结论 丙戊酸钠作为辅助精神分裂症用药,其安全性佳,各项指标改善,可作为临床推广药物。

Objective To analyze the clinical efiect of sodium valproate adjuvant therapy in patients with schizophrenia. Methods One hundred and twenty schizophrenic patients collected in our hospital from January 3, 2014 to January 1, 2016 were divided into study group(n=60) and control group(n=60) according to the treatment period. The control group was treated with olanzapine, and the study group was treated with sodium valproate on the basis of the control group. PANSS, MOAS and adverse reactions of the two groups before and after treatment were recorded. The scores of Psychiatric Rating Scale(BPRS), side efiects scale(TESS) and schizophrenia cognitive function battery(MCCB) were compared between the two groups. Results The PANSS scores of the two groups at the first, second and fourth weekend after treatment were significantly lower than those before treatment(P<0.05). At the second and fourth weekend of treatment, PANSS score of the study group was lower than that of the control group, and there was significant difierence between the two groups(P<0.05);The MOAS scores of the study group and the control group at each stage after treatment were lower than those before treatment, and there were difierences between the groups(P<0.05). The MOAS scores of the study group were lower than those of the control group at the second and fourth weekend of treatment, and there was statistical significance between the groups(P<0.05);There was no significant difierence in the incidence of adverse reactions between the two groups(P>0.05). After treatment,the scores of BPRS and TESS in the study group were lower than those in the control group, and the score of MCCB was higher than that in the control group. There was a difierence(P<0.05). It was improved after symptomatic treatment. Conclusion As an adjunctive drug for schizophrenia,valproate has better safety and can be used for clinical promotion.